Liver

By M. Sa’adeh. Laboratory Investigation, 2016

1,163 citations recorded by the source corpus.

prior to 1998 were excluded. Survival was defined as the time from initial biopsy to eGFR < 15mL/min, renal replacement therapy, or death. Immunotherapy (IMT) was defined as any treatment with cyclophosphamide, azathioprine, mycophenolate mofetil, or rituximab. Results: 211 patients had follow-up data (AA=80, W=106, Asian=7, NS=18). African Americans (AA) had a larger proportion of class V LN at presentation (27% vs. 16%, p=0.04). Age, BP, BMI, Diabetes, SCr, 24h protein, C3, C4, ANA, and anti-dsDNA Ab positivity were similar between AA and white patients. Results are mean (SD). Baseline characteristics of other groups were not different (not shown). Overall, AA had shorter survival compared to white patients [HR 1.7, 95% CI: 1.0 to 2.8, p=0.042]. Similarly, AA without IMT had shorter survival compared to white patients without IMT [HR 2.2, 95% CI: 1.0 to 4.8, p=0.046]. However, AA with IMT did not have different survival compared to white patients with IMT [HR 1.1, 95% CI: 0.5 to 1.1 , p=0.71]. Conclusions: Immunotherapy reduces the risk for progression to ESRD and closes the gap in racial disparities between African American and white patients.

Subfields: Epidemiology

View Paper: https://www.semanticscholar.org/paper/34f40a2b8b8b966a37b5ab3e04ff090c14fdb1d0